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Abstract
A prostate cancer committee was established to modify the NCCN 
Clinical Practice Guidelines in Oncology (NCCN Guidelines) on Pros-
tate Cancer for adaptation and implementation in the Middle East 
and North Africa (MENA) region. The objective was to enhance the 
multidisciplinary approach to the treatment of prostate cancer. The 
committee, comprising regional experts in the fields of urologic, 
medical, and radiation oncology, reviewed the 2009 version of the 
NCCN Guidelines on Prostate Cancer and suggested modifications 
based on the unique needs of the regions determined through 
published evidence and local expertise. The committee identified 
several areas in the NCCN Guidelines that they believed required 
modification, which are presented in this article. The treatment of 
Prostate cancer is a significant source of morbidity and 
mortality in the West, and remains the second lead-
ing cause of death from a solid malignancy in men in 
the United States.1 However, its effect on populations 
in the Middle East and North Africa (MENA) region 
is not completely known. A prostate cancer commit-
tee was established to modify the NCCN Clinical Prac-
tice Guidelines in Oncology (NCCN Guidelines) on 
Prostate Cancer for adaptation and implementation in 
the MENA region. The objective was to enhance the 
multidisciplinary approach to the treatment of prostate 
cancer. The committee, comprising regional experts in 
the fields of urologic, medical, and radiation oncology, 
reviewed the 2009 version of the NCCN Guidelines 
on Prostate Cancer and suggested modifications based 
on the unique needs of the region determined through 
published evidence and local expertise. The committee 
identified several areas in the NCCN Guidelines that 
they believed required modification, which are present-
ed in this article. The treatment of prostate cancer in 
the MENA region has numerous challenges. The hope 
is that this effort to modify the NCCN Guidelines on 
Prostate Cancer for practical use in the MENA region 
will improve regional awareness and patient care.
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prostate cancer in the MENA region has numerous challenges. The 
hope is that this effort to modify the NCCN Guidelines on Prostate 
Cancer for practical use in the MENA region will improve regional 
awareness and patient care. (JNCCN 2010;8[Suppl 3]:S26–S28)
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Diagnosis and Staging
Because PSA screening is not routine in the MENA 
region, patients tend to present with more advanced 
disease. A general lack of primary care exists in 
the health systems of the region, which represents 
a challenge to timely diagnosis. Transrectal sonog-
raphy is not routinely available except in regional 
centers, and experience with transrectal sonographic 
biopsy of the prostate also seems to be limited to re-
gional centers. Similarly, experience with the patho-
logic diagnosis of prostate cancer (including the nu-
ances of grading) is also limited to referral centers. 
Although CT and nuclear bone scans are generally 
available, MRI has more limited availability.
Treatment
The definitive and palliative treatment of prostate 
cancer has multiple regional challenges. Definitive 
treatment typically involves either surgery or radio-
therapy, and experience in the management of this 
disease is generally lacking. A brief poll of urologists, 
for example, found that awareness of the existence 
of NCCN Guidelines on Prostate Cancer varied be-
tween 5% and 86%.
Adequate experience in the surgical manage-
ment of prostate cancer has been shown to improve 
outcomes.6 A lack of surgical experience in the local-
ized management of prostate cancer generally exists, 
even in referral centers, and radiation therapy has 
similar issues. According to the International Atom-
ic Energy Agency (IAEA), only 93 machines are ca-
pable of delivering greater than 10 mV of energy in 
a region of 730 million people.7 More importantly, 
70 machines are clustered in 3 countries (Turkey, 
Egypt, and KSA), leaving 23 machines to service the 
needs of 19 countries. Only 30 of 93 machines are 
capable of delivering CT dosimetry and planning. 
Furthermore, the costs of neoadjuvant hormonal 
therapy in combination with radiation therapy are 
also challenging, and experience with brachytherapy 
is limited.
Similar issues arise when addressing the manage-
ment of advanced disease. Although the cost of hor-
monal ablation is prohibitive, bilateral orchiectomy 
is a viable option and available. Access to systemic 
chemotherapy is limited, palliative care specialists 
are few, and the availability of narcotics tends to 
be limited.
The Region
For the purposes of this section, the MENA region 
refers to Afghanistan, Algeria, Armenia, Egypt, 
Ethiopia, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, 
Oman, Pakistan, Qatar, Kingdom of Saudi Arabia 
(KSA), Somalia, Sudan, Syria, Tunis, Turkey, United 
Arab Emirates (UAE), and Yemen. This collection 
of countries is obviously extremely heterogeneous 
in terms of economic resources and health care in-
frastructure. Although generalizations are difficult, 
some pertinent issues and challenges are broadly ap-
plicable to this region.
Incidence
Although the exact incidence of prostate cancer in 
the MENA region is unknown, the reported inci-
dence is approximately 5.8 cases per 100,000, with 
a mortality rate of 4.9 cases per 100,000.2 The accu-
racy of these data is not clear, however, because they 
are derived from unweighted averages from other 
regions. In general, prostate-specific antigen (PSA) 
screening is not routine, and therefore whether the 
lower incidence rate is secondary to the absence of 
screening or from a truly lower prevalence in the 
population is unknown. Smaller regional cancer 
databases, however, suggest that the true impact of 
this disease may be more significant than generally 
perceived. Young3 reported on regional cancer da-
tabases from 8 countries in the MENA region (Jor-
dan, Egypt, Bahrain, KSA, Kuwait, Qatar, Oman, 
and UAE), and found that prostate cancer ranked 
among the top 4 malignancies in terms of frequency 
in 5 countries.3 Shamseddine et al.4 reported that 
prostate cancer represented the most frequently re-
ported malignancy in Lebanese men.
In general it is the committee’s perception that 
most patients present with late-stage disease because 
of the lack of PSA screening. It is also important to 
consider that the MENA region population is ap-
proximately 750 million.5
Because 65% of the population is currently 
younger than 30 years, even if the incidence of pros-
tate cancer is lower than that of the West, the scope 
of the problem will only become more significant 
over the next 20 years as the population ages and 
presumably has access to improved medical care.
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Recommendations
Based on these challenges, the committee recom-
mended the following modifications to the NCCN 
Guidelines on Prostate Cancer.
Staging Workup
Staging with CT/MRI seems restrictive for stage 1 
to 2, which limits these imaging modalities to those 
patients with a 20% or more probability of lymph 
node involvement. Given that expertise in treat-
ment is limited, a diagnosis of metastatic disease 
would potentially avoid needless definitive interven-
tion. Therefore, the committee believed that a cutoff 
of 10% would be more appropriate.
Expected Patient Survival
Life expectancy estimates from data obtained in the 
developed world may not be representative of the 
MENA region. Morbidity and mortality from the 
same illness may be more severe because of genetic 
factors, access to health care facilities, and availabil-
ity of technology, socioeconomics, and education. 
Barring the availability of country-specific life ex-
pectancy tables, the committee recommends a com-
bination of factors, including performance status, 
comorbid conditions, disease stage, and physician 
judgment based on local experience.
Initial Therapy
Although data show that a certain percentage of pa-
tients with locally advanced disease (T3b–T4) may 
be treated with surgery, the availability of surgical 
expertise for treating this patient population is ex-
tremely limited. Surgery is not recommended as an 
option, except in the rare institutions with a high 
level of surgical expertise.
Primary Salvage Therapy
Because experience with cryotherapy or brachyther-
apy is extremely limited, the management of post-
radiation recurrence with either of these modalities 
should be restricted to a research setting.
Systemic Salvage Therapy
As stated in the NCCN guidelines, the clinical ben-
efit of antiandrogens in hormone-refractory disease 
is limited. Given that the cost of these medications 
is prohibitive for a significant segment of the popula-
tion, the committee suggests the daily use of diethyl-
stilbestrol in low doses (1–3 mg) in combination with 
warfarin as an affordable second-line alternative. 
Diethylstilbestrol has been shown to result in PSA 
declines in up to 42% of patients with rising PSA.8
Principles of Radiation Therapy
Although the NCCN guidelines do not mention 
high–dose-rate brachytherapy in the principles of ra-
diation therapy, the committee believes that guide-
lines for the use of this technology should be incor-
porated.
Summary
The treatment of prostate cancer in the MENA re-
gion is a challenge and numerous obstacles hinder 
the delivery of what would be deemed appropriate 
care in the West. Although the incidence of prostate 
cancer seems to be less than in the West, the true 
incidence probably is at least partially understated. 
Physician awareness of appropriate treatment guide-
lines may not be sufficient; the hope is that this ini-
tial effort in tailoring guidelines to the region will 
lead to improved patient care.
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